Previous Close | 39.38 |
Open | 39.18 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 39.12 - 39.42 |
52 Week Range | 37.88 - 53.86 |
Volume | |
Avg. Volume | 1,307,054 |
Market Cap | 255.502B |
Beta (5Y Monthly) | 0.21 |
PE Ratio (TTM) | 16.37 |
EPS (TTM) | 2.40 |
Earnings Date | N/A |
Forward Dividend & Yield | 1.24 (3.10%) |
Ex-Dividend Date | Mar 17, 2022 |
1y Target Est | 47.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for RHHBY
Roche Holding Ltd (OTC: RHHBF) (OTC: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. The XBB.1.5 Omicron sub-variant is prevalent in the U.S. and quickly spreads to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment stra
Roche has launched a new PCR test to detect a fast-spreading sub-variant of the Omicron variant of Coronavirus, the Swiss drugmaker said on Thursday. The new test specifically targets the XBB.1.5 Omicron variant and will help researchers closely track the virus’s lineage and provide insights into the epidemiology and impact it has on public health, the company added. The XBB.1.5 variant is prevalent in the United States and is quickly spreading to other countries, Roche said.
This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler® 480 II* and cobas® z480.Results from the test will help closely track the virus’ lineage and provide insights into the epidemiology and impact it has on public health.Concern from the World Health Organisation centres around the XBB.1.5 high transmissibility and growth advantage.1 Basel, 26 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB